A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability,
PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with
HER2-positive advanced solid tumors with or without brain metastases.
The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041
monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c
(dose expansion with ZN-A-1041 combination therapy).